FLRG Inhibitors

FLRG inhibitors as classified here are a group of chemicals that indirectly influence FLRG activity through modulation of the TGF-β signaling pathway. These inhibitors target various components of the TGF-β signaling cascade, which is known to intersect with the regulatory functions of FLRG in cellular processes. The molecules listed are primarily inhibitors of TGF-β receptors or affectors of TGF-β signaling, which can result in a downstream impact on FLRG's role in the modulation of this pathway. For instance, molecules like SB431542, LY364947, and A-83-01 are inhibitors that specifically target the TGF-β type I receptor ALK5 and related kinases, which are critical mediators of TGF-β signaling.

The inhibition of ALK5 by these compounds can lead to a reduction in the signaling that is responsible for various cellular responses, including those associated with FLRG activity. Other inhibitors, like SD-208 and Galunisertib, act similarly by targeting TGF-β receptor kinases, which play a pivotal role in the propagation of TGF-β signals. By impeding these kinases, these inhibitors can potentially alter the regulatory effects that FLRG has in TGF-β signaling.

Additional compounds like Pirfenidone and Tranilast exert their inhibitory effects by decreasing the levels or activity of TGF-β itself, which may also lead to changes in FLRG function given its role in TGF-β modulation. Halofuginone and RepSox further exemplify this class, targeting the downstream Smad3 phosphorylation process and ALK5, respectively, thereby potentially influencing the functional dynamics of FLRG in relation to TGF-β signaling.

Lastly, agents like EW-7197 and LY2109761 are considered in this context for their ability to inhibit TGF-β receptor kinase activity, which is expected to have a consequential impact on FLRG activity.